Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30457919 | 0.82 | S1PR1 (0.41) | AHRSLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL21821087 | 0.82 | S1PR1 (0.41) | AHRSLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL27810411 | 0.82 | SLC6A2 (0.46) | AHRSLC6A4SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL11635848 | 0.82 | CYP3A4 (0.45) | SLC6A4SLC6A2SLC6A3ALDH1A1LMNA | |
| SCHEMBL10607615 | 0.81 | ALDH1A1 (0.49) | AHRSLC6A4SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL27886399 | 0.80 | SLC6A2 (0.34) | SLC6A4SLC6A2SLC6A3ALDH1A1LMNA | |
| SCHEMBL27868723 | 0.80 | APP (0.41) | SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL27814751 | 0.80 | SLC6A2 (0.45) | SLC6A4SLC6A2SLC6A3ALDH1A1LMNA | |
| SCHEMBL254524 | 0.80 | AHR (0.50) | AHRSLC6A4SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL10867874 | 0.78 | AHR (0.48) | AHRSLC6A4SLC6A2SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20210221809-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2021-07-22 | — | — | US | disclosed |
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2021-05-04 | — | — | US | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery ENSCM (FR) | 2020-09-10 | — | — | US | disclosed |
| EP-3377491-B1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2019-11-13 | — | — | EP | disclosed |
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | UNIV RUTGERS (US) | 2019-01-31 | — | — | US | disclosed |
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | UNIV RUTGERS (US) | 2019-01-31 | — | — | US | disclosed |
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-0868420-B1 | 3-PYRAZOLECARBOXAMIDE DERIVATIVES HAVING CANNABINOID RECEPTOR AFFINITY | SANOFI SYNTHELABO (FR) | 2000-03-29 | — | — | EP | disclosed |
| US-5925768-A | ANTIINFLAMMATORY AGENTS; ANALGESICS, ANTICOAGULANTS, NARCOTICS | SANOFI (FR) | 1999-07-20 | — | — | US | disclosed |
| EP-0885889-A2 | Process for the preparation of pyrazole-3-carboxylic acids | SANOFI (FR) | 1998-12-23 | — | — | EP | disclosed |
| EP-0868420-A1 | 3-PYRAZOLECARBOXAMIDE DERIVATIVES HAVING CANNABINOID RECEPTOR AFFINITY | SANOFI (FR) | 1998-10-07 | — | — | EP | disclosed |
| WO-1997021682-A1 | 3-PYRAZOLECARBOXAMIDE DERIVATIVES HAVING CANNABINOID RECEPTOR AFFINITY | SANOFI (FR) | 1997-06-19 | — | — | WO | disclosed |
| US-4633026-A | DEHYDROHALOGENATION OF RING-HALOGENATED ALPHA- OR BETA-BROMOETHYL BENZENES WITH STRONG BASE, POLYOXYETHYLENE GLYCOL CATALYST, AMINE POLYMERIZATION INHIBITOR | ETHYL CORPORATION (US) | 1986-12-30 | — | — | US | disclosed |
| US-4081596-A | DIURETIC, SALURETIC, ANTIHYPERTENSIVE, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-28 | — | — | US | disclosed |
| US-4005215-A | DIURETIC | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-25 | — | — | US | disclosed |
| US-3978077-A | DIURETIC, HYPOTENSIVE, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (GB) | 1976-08-31 | — | — | US | disclosed |
| US-3957814-A | DIURETICS, SALURETICS, HYPOTENSIVE AGENTS, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | AHR 3695/4885SLC6A4 372/4885SLC6A2 98/4885 |
| US-10995089-B2 | Zaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | AHR 1074/4885SLC6A4 2114/4885SLC6A2 1708/4885 |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | AHR 2001/4885SLC6A4 229/4885SLC6A2 832/4885 |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | AHR 1288/4885SLC6A4 2247/4885SLC6A2 1318/4885 |
| US-20210221809-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK3 | AHR 1288/4885SLC6A4 2247/4885SLC6A2 1318/4885 |
| US-20200283432-A1 | ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK3 | AHR 1074/4885SLC6A4 2114/4885SLC6A2 1708/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | AHR 2001/4885SLC6A4 229/4885SLC6A2 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.